Aspirin could reduce colon cancer risk, new study reveals

GUWAHATI: Aspirin, as we know is used to treat pain, and reduce fever or inflammation, but a new study has found the drug to be potential in reduction in colon cancer risk.

The study is based on findings related to regular aspirin use and a reduction in the risk of colon cancer and other digestive tract cancers.

Researchers concluded that aspirin had been associated with a 22 to 39 percent reduction in the risk of these types of cancers.

However, the study has also warned that the potential reduction in heart disease risk from taking aspirin regularly may not be worth the potential increased risk of bleeding.

The new paper reviewed 113 studies, including studies on colon cancer, stomach cancer, pancreatic cancer, and cancers of the head, neck, esophagus, liver, gallbladder, and bile ducts.

The researchers, based in Italy, found an aspirin dose between 75 and 100 milligrams a day reduced the risk of colon cancer by 10 percent. A 325 mg per day dose reduced the risk by 35 percent.

This means the benefits of aspirin increased with higher dosage.

The study also notes that the benefits increased the longer people took the aspirin.

But more and longer isn’t necessarily better for everyone.

After years of recommendations that daily aspirin could help prevent heart attacks and stroke in people with a higher risk for those cardiovascular issues, research in 2018 and 2019 began to change that opinion.

That research essentially found that while aspirin did provide a reduction in heart disease risk, more people suffered bleeding complications, including in the gastrointestinal tract, due to aspirin than avoided a heart attack or stroke.

The same balancing act between potential benefits and risk needs to be assessed when it comes to cancer and aspirin, experts said.